Anglo-Swedish drug major AstraZeneca reported a profit increase in its fourth quarter of $960 million compared to last year's $901 million.
Earnings per $0.25 ordinary share were $0.62 compared to $0.58. Core earnings per share (EPS) were $1.45, up 7% at constant exchange rates (CER).
Fourth quarter total revenue was $12.02 billion compared to $11.21 billion in the previous year. Total revenue excluding Covid-19 products was $12.04 billion, up 16% at CER. Product sales were $11.32 billion compared to $10.80 billion.
Fiscal 2023 core EPS increased 15%, at CER, to $7.26. Total revenue was $45.81 billion, up 6%.
Excluding Covid-19 medicines, total revenue increased 15% and product sales increased 14% for fiscal year, at CER.
For fiscal 2024, at CER, total revenue is expected to increase by a low double-digit to low teens percentage. Core EPS is expected to increase by a low double-digit to low teens percentage.